Why do patients with psychosis use cannabis and are they ready to change their use?

International Journal of Developmental Neuroscience

Volumn 29, Issue 3, 2011, Pages 335-346

  Kolliakou, Anna ^a   Joseph, Candice ^a   Ismail, Khalida ^a   Atakan, Zerrin ^a   Murray, Robin M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cannabis use; Psychosis; Readiness to change; Reasons for use; Schizophrenia; Substance use

Indexed keywords

ARTICLE; CANNABIS ADDICTION; CANNABIS SMOKING; COMORBIDITY; DISEASE EXACERBATION; DYSPHORIA; FIRST EPISODE PSYCHOSIS; GENETIC PREDISPOSITION; GENOTYPE ENVIRONMENT INTERACTION; HIGH RISK POPULATION; HUMAN; MOTIVATION; NEUROPATHOLOGY; PATIENT ATTITUDE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOANALYSIS; PSYCHOPHARMACOLOGY; PSYCHOSIS; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SELF MEDICATION; SELF REPORT;

CANNABIS; COMORBIDITY; HUMANS; MARIJUANA ABUSE; MODELS, THEORETICAL; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTIC DISORDERS; RISK FACTORS; SCHIZOPHRENIA; SELF MEDICATION; SELF REPORT;

CANNABIS;

EID: 79953304239     PISSN: 07365748     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2010.11.006     Document Type: Article

References (121)

1. Addington J., Addington D. Patterns, predictors and impact of substance use in early psychosis: a longitudinal study. Acta Psychiatr. Scand. 2007, 115:304-309.
2. Addington J., Duchak V. Reasons for substance use in schizophrenia. Acta Psychiatr. Scand. 1997, 96:329-333.
3. Andreasson S., Allebeck P., Engstrom A., Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987, 2:1483-1486.
4. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., Moffitt T.E. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 2002, 325:1212-1213.
5. Baigent M., Holme G., Hafner R.J. Self reports of the interaction between substance abuse and schizophrenia. Aust. N Z J. Psychiatry 1995, 29(1):69-74.
6. Bandura A. Social Learning Theory 1977, General Learning Press, New York.
7. Barnett J.H., Werners U., Secher S.M., Hill K.E., Brazil R., Masson K., Pernet D.E., Kirkbride J.B., Murray G.K., Bullmore E.T., Jones P.B. Substance use in a population-based clinic sample of people with first-episode psychosis. Br. J. Psychiatry 2007, 190:515-520.
8. Barrowclough C., Haddock G., Lowens I., Allott R., Earnshaw P., Fitzsimmonds M., Nothard S. Psychosis and drug and alcohol problems. Clinical Handbook of Co-existing Mental Health and Drug and Alcohol Problem 2007, Routledge, London. A. Baker, R. Velleman (Eds.).
9. Barrowclough C., Ward J., Wearden A., Gregg L. Expressed emotion and attributions in relatives of schizophrenia patients with and without substance misuse. Soc. Psychiatry Psychiatr. Epidemiol. 2005, 40(11):884-891.
10. Bellack A.S., Gold J.M., Buchanan R.W. Cognitive rehabilitation for schizophrenia: problems, prospects, and strategies. Schizophr. Bull. 1999, 25(2):257-274.
11. Blanchard J.J., Brown S.A., Horan W.P., Sherwood A.R. Substance use disorders in schizophrenia: review, integration, and a proposed model. Clin. Psychol. Rev. 2000, 20(2):207-234.
12. Boydell J., van Os J., McKenzie K., Murray R.M. The association of inequality with the incidence of schizophrenia-an ecological study. Soc. Psychiatry Psychiatr. Epidemiol. 2004, 39:597-599.
13. Brady S., Hiam C.M., Saemann R., Humbert L., Fleming M.Z., Dawkins-Brickhouse K. Dual diagnosis: a treatment model of substance abuse and major mental illness. Community Mental Health J. 1996, 32:573-578.
14. Buchanan R.W., Davis M., Goff D., Green M.F., Keefe R.S., Leon A.C., Nuechterlein K.H., Laughren T., Levin R., Stover E., Fenton W., Marder S.R. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr. Bull. 2005, 31(1):5-19.
15. Cannon M., Jones P.B., Murray R.M. Obstetric complications and schizophrenia: historical and meta-analytic review. Am. J. Psychiatr. 2002, 159:1080-1092.
16. Cannon M., Caspi A., Moffitt T.E., Harrington H., Taylor A., Murray R.M., Poulton R. Evidence for early childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. Arch. Gen. Psychiatry 2002, 59:449-456.
17. Cardno A.G., Jones L.A., Murphy K.C., Sanders R.D., Asherson P., Owen M.J., McGuffin P. Dimensions of psychosis in affected sibling pairs. Schiz. Bull. 1999, 25(4):841-850.
18. Carey K.B., Purnine D.M., Maisto S.A., Carey M.P. Assessing readiness to change substance abuse: a critical review of instruments. Clin. Psychol. Sci. Prac. 1999, 6:245-266.
19. Carey K.B., Carey M.P., Simons J.S. Correlates of substance use disorder among psychiatric outpatients: focus on cognition, social role functioning, and psychiatric status. J. Nerv. Ment. Dis. 2003, 191(5):300-308.
20. Carey K.B., Purnine D.M., Maisto S.A., Carey M.P. Correlates of stages of change for substance abuse among psychiatric outpatients. Psychol. Addict. Behav. 2002, 16(4):283-289.
21. Carey K.B., Maisto S.A., Carey M.P., Purnine D.M. Measuring readiness-to-change substance misuse among psychiatric outpatients: I. Reliability and validity of self-report measures. J. Stud. Alcohol. 2001, 62(1):79-88.
22. Carey K.B., Purnine D.M., Maisto S.A., Carey M.P., Barnes K.L. Decisional balance regarding substance use among persons with schizophrenia. Community Ment. Health J. 1999, 35(4):289-299.
23. Clark D., Fairburn C. Science and Practice of Cognitive Behaviour Therapy 2009, Oxford University Press, Oxford and New York.
24. Cooper M.L. Motivations for alcohol use among adolescents: development and validation of a four factor model. Psychol. Assess. 1994, 6:117-128.
25. Dekker N., Linszen D.H., Haan L.D. Reasons for cannabis use and effects of cannabis use as reported by patients with psychotic disorders. Psychopathology 2009, 42:350-360.
26. Dickey B., Azeni H., Weiss R., Sederer L. Schizophrenia, substance use disorders and medical co-morbidity. J. Mental Health Policy Econ. 2000, 3:27-33.
27. DiClemente C. Addiction and Change: How Addictions Develop and Addicted People Recover 2003, Guilford Press, New York.
28. DiClemente C.C., Nidecker M., Bellack A.S. Motivation and the stages of change among individuals with severe mental illness and substance abuse disorders. J. Subst. Abuse Treat. 2008, 34(1):25-35.
29. DiClemente C.C., Hughes S.O. Stages of change profiles in outpatient alcoholism treatment. J. Subst. Abuse 1990, 2(2):217-235.
30. Di Forti M., Morgan C., Dazzan P., Pariante C., Mondelli V., Marques T.R., Handley R., Luzi S., Russo M., Paparelli A., Butt A., Stilo S.A., Wiffen B., Powell J., Murray R.M. High-potency cannabis and the risk of psychosis. Br. J. Psychiatry 2009, 195(6):488-491.
31. Di Forti M., Lappin J.M., Murray R.M. Risk factors for schizophrenia - all roads lead to dopamine. Eur. Neuropsychopharmacol. 2007, 17(2):101-107.
32. Dixon L., Haas G., Weiden P.J., Sweeney J., Frances A.J. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am. J. Psychiatry 1991, 148:224-230.
33. Drake R.E., Mueser K.T., Brunette M.F., McHugo G.J. A review of treatments for people with severe mental illnesses and co-occurring substance use disorders. Psychiatr. Rehabil. J. 2004, 27(4):360-374.
34. D'Souza D.C., Abi-Saab W.M., Madonick S., Forselius-Bielen K., Doersch A., Braley G., Gueorguieva R., Cooper T.B., Krystal J.H. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol. Psychiatry 15 2005, 57(6):594-608.
35. D'Souza D.C., Perry E., MacDougall L., Ammerman Y., Cooper T., Wu Y.T., Braley G., Gueorguieva R., Krystal J.H. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004, 29:1558-1572.
36. Fergusson D.M., Horwood L.J., Ridder E.M. Tests of causal linkages between cannabis use and psychotic symptoms. Addiction 2005, 100:354-366.
37. Fowler I.L., Carr V.J., Carter N.T., Lewin T.J. Patterns of current and lifetime substance use in schizophrenia. Schizophr. Bull 1998, 24:443-445.
38. Goswami S., Mattoo S.K., Basu D., Singh G. Substance-abusing schizophrenics: do they self-medicate?. Am. J. Addict. 2004, 13:139-150.
39. Grech A., van Os J., Jones P.B., Lewis S.W., Murray R.M. Cannabis use and outcome of recent onset psychosis. Eur. Psychiatry 2005, 20(4):349-353.
40. Green B., Young R., Kavanagh D. Cannabis use and misuse prevalence among people with psychosis. Br. J. Psychiatry 2005, 187:306-313.
41. Green B., Kavanagh D.J., Young R.M.C.D. Reasons for cannabis use in men with or without psychosis. Drug. Alcohol. Rev. 2004, 23:445-453.
42. Gregg L., Haddock G., Barrowclough C. Self-reported reasons for substance use in schizophrenia: a Q methodological investigation. Ment. Health. Subst. Use 2009, 2(1):24-39.
43. Gregg L., Barrowclough C., Haddock G. Reasons for increased substance use in psychosis. Clin. Psychol. Rev. 2007, 27:494-510.
44. Hambrecht M., Häfner H. Substance abuse and the onset of schizophrenia. Biol. Psychiatry 1996, 40(11):1155-1163.
45. Hao S., Avraham Y., Mechoulam R., Berry E.M. Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur. J. Pharmacol. 2000, 392:147-156.
46. Harrison I., Joyce E.M., Mutsatsa S.H., Hutton, Huddy V., Kapasi M., Barnes T.R.E. Naturalistic follow-up of co-morbid substance use in schizophrenia: the West London first-episode study. Psychol. Med. 2007, 38:79-88.
47. Hashibe M., Straif K., Tashkin D.P., Morgenstern H., Greenland S., Zhang Z.F. Epidemiologic review of marijuana use and cancer risk. Alcohol 2005, 35:265-275.
48. Hawton K., Sutton L., Haw C., Sinclair J., Deeks J. Schizophrenia and suicide: systematic review of risk factors. Br. J. Psychiatry 2005, 187:9-20.
49. Hayes S.C., Wilson K.G., Gifford E.V., Follette V.M., Strosahl K. Experimental avoidance and behavioral disorders: a functional dimensional approach to diagnosis and treatment. J. Consult Clin. Psychol. 1996, 64(6):1152-1168.
50. Heather N., Smailes D., Cassidy P. Development of a Readiness Ruler for use with alcohol brief interventions. Drug Alcohol Depend. 2008, 98(3):235-240.
51. Heather N., Luce A., Peck D., Dunbar B., James I. Development of a treatment version of the readiness to change questionnaire. Addiction Res. 1999, 7(1):63-83.
52. Henquet C., Krabbendam L., Spauwen J., Kaplan C., Lieb R., Wittchen H.U., van Os J. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. BMJ 2005, 330:11-15.
53. Hides L., Lubman D.I., Dawe S. Models of co-occurring substance misuse and psychosis: are personality traits the missing link?. Drug Alcohol Rev. 2004, 23:425-432.
54. Home Office, 2009/2010. British Crime Survey. HMSO, London.
55. Isaac M., Isaac M., Holloway F. Is cannabis an anti-antipsychotic? The experience in psychiatric intensive care. Human Psychopharm. 2005, 20:207-210.
56. James W., Preston N.J., Koh G., Spencer C., Kisely S.R., Castle D.J. A group intervention which assists patients with dual diagnosis reduce their drug use: a randomized controlled trial. Psychol Med. 2004, 34(6):983-990.
57. Janssen B., Gaebel W., Haerter M., Komaharadi F., Lindel B., Weinmann S. Evaluation of factors influencing medication compliance in inpatient treatment of psychotic disorders. Psychopharmacology (Berl) 2006, 187(2):229-236.
58. Kapur S., Mizrahi R., Li M. From dopamine to salience to psychosis--linking biology, pharmacology and phenomenology of psychosis. Schizophr. Res. 2005, 79(1):59-68.
59. Kavanagh D.J., Waghorn G., Jenner L., Chant D.C., Carr V., Evans M., Hemnan H., Jablensky A., McGrath J.J. Demographic and clinical correlates of comorbid substance use disorders in psychosis: multivariate analyses from an epidemiological sample. Schizophr. Res. 2004, 66:115-124.
60. Kendler K.S., McGuire M., Gruenberg A.M., O'Hare A., Spellman M., Walsh D. The Roscommon Family Study. I. Methods, diagnosis of probands, and risk of schizophrenia in relatives. Arch. Gen. Psychiatry 1993, 50(7):527-540.
61. Khantzian E.J. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications. Harv. Rev. Psychiatry 1997, 4:231-244.
62. Khantzian E.J. The self medication hypothesis of addictive disorders. Am. J. Psychiatry 1985, 142:1259-1264.
63. Kuperberg G., Heckers S. Schizophrenia and cognitive function. Curr. Opin. Neurobiol. 2000, 10(2):205-210.
64. LaBrie J.W., Quinlan T., Schiffman J.E., Earleywine M.E. Performance of alcohol and safer sex change rulers compared with readiness to change questionnaires. Psychol. Addict Behav. 2005, 19(1):112-115.
65. Lambert M., Conus P., Lubman D.I., Wade D., Yuen H., Moritz S., Naber D., McGorry P.D., Schimmelmann B.G. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. Acta Psychiatr Scand. 2005, 112(2):141-148.
66. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(17):9235-9240.
67. Laudet A.B., Magura S., Vogel H.S., Knight E.L. Perceived reasons for substance misuse among persons with a psychiatric disorder. Am. J. Orthopsychiatry 2004, 74(3):365-375.
68. Linszen D.H., Dingermans P.M., Lenior M.E. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch. Gen. Psychiatry 1994, 31:273-279.
69. Lobbana F., Barrowclough C., Jeffery S., Bucci S., Taylor K., Mallinson S., Fitzsimmons M., Marshall M. Understanding factors influencing substance use in people with recent onset psychosis: a qualitative study. Soc. Sci. Med. 2010, 70(8). 1141-1117.
70. Marlatt G.A., Gordon J.R. Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviours 1985, Guildford Press, New York.
71. McCleery A., Addington J., Addington D. Substance misuse and cognitive functioning in early psychosis: a 2 year follow-up. Schizophrenia Res. 2006, 88:187-191.
72. McCreadie R.G. Use of drugs, alcohol and tobacco by people with schizophrenia: case-control study. Br. J. Psychiatry 2002, 181:321-325.
73. McGrath J., Welham J., Scott J., Varghese D., Degenhardt L., Hayatbakhsh M.R., Alati R., Williams G.M., Bor W., Najman J.M. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch. Gen. Psychiatry 2010, 67(5):440-447.
74. Menezes P.R., Johnson S., Thornicroft G., Marshall J., Prosser D., Bebbington P., Kuipers E. Drug and alcohol problems among individuals with severe mental illness in south London. Br. J. Psychiatry 1996, 168:612-619.
75. Miles H., Johnson S., Amponsah-Afuwape S., Finch E., Leese M., Thornicroft G. Characteristics of subgroups of individuals with psychotic illness and a comorbid substance use disorder. Psychiatr. Serv. 2003, 54:554-561.
76. Miller W.R. Motivation for treatment: a review with special emphasis on alcoholism. Psychol. Bull. 1985, 98(l):84-107.
77. Miller W.R., Rollnick S. Motivational Interviewing 2002, Guildford Press, New York. second ed.
78. Miller W.R., Tonigan J.S. Assessing drinkers' motivation for change: the stages of change readiness and treatment eagerness scale (SOCRATES). Psychol. Addict. Behav. 1996, 10:81-89.
79. Morrison P.D., Zois V., McKeown D.A., Lee T.D., Holt D.W., Powell J.F., Kapur S., Murray R.M. The acute effects of synthetic intravenous Delta-9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol. Med. 2009, 39(10):1607-1616.
80. Mueser K.T., Drake R.E., Turner W., McGovern M. Comorbid substance use disorders and psychiatric disorders. Rethinking Substance Abuse 2006, 115-133. Guilford Press, New York. W.R. Miller, K.M. Carroll (Eds.).
81. Mueser K.T., Yarnold P.R., Rosenberg S.D., Swett C., Miles K.M., Hill D. Substance use disorder in hospitalized severely mentally ill psychiatric patients: prevalence, correlates and subgroups. Schizophr. Bull. 2000, 26:179-192.
82. Mueser K.T., Drake R.E., Wallach M.A. Dual diagnosis: a review of etiological theories. Addict. Behav. 1998, 23(6):717-734.
83. Mueser K.T., Bennett M., Kushner M.G. Epidemiology of substance use disorders among persons with chronic mental illnesses. Double Jeopardy: Chronic Mental Illness and Substance Abuse 1995, 9. Harwood Academic Publishers, New York. A.F. Lehman, L. Dixon (Eds.).
84. Nelson K., Walsh D., Deeter P., Sheehan F.A. Phase II study of delta-9 tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J. Pall. Care 1994, 10:14-18.
85. Owen M.J., O'Donovan M., Gottesman I.I. Psychiatric Genetics and Genomics 2003, Oxford University Press, Oxford.
86. Pantalon M.V., Swanson A.J. Use of the University of Rhode Island Change Assessment to measure motivational readiness to change in psychiatric and dually diagnosed individuals. Psychol. Addict. Behav. 2003, 17(2):91-97.
87. Pantalon M.V., Nich C., Frankforter T., Carroll K.M. The URICA as a measure of motivation to change among treatment-seeking individuals with concurrent alcohol and cocaine problems. Psychol. Addict. Behav. 2002, 16(4):299-307.
88. Paparelli, A., Di Forti, M., Morrison, P.D, Murray, R.M. Drug-induced psychosis: how to avoid star gazing in schizophrenia research by looking at the real cause. Front. Behav. Neurosci., submitted for publication.
89. Parrott A. Drug taking- for better or for worse?. Psychologist 2008, 21(11):924-927.
90. Pencer A., Addington J. Substance use and cognition in early psychosis. J. Psychiatry Neurosci. 2003, 28(1):48-54.
91. Peters E.R., Joseph S.A., Garety P.A. Measurement of delusional ideation in the normal population: introducing the PDI (Peters et al. Delusions Inventory). Schizophr. Bull. 1999, 25(3):553-576.
92. Potter D.J., Clark P., Brown M.B. Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology. J. Forensic Sci. 2008, 53(1):90-94.
93. Potvin S., Briand C., Prouteau A., Bouchard R.H., Lipp O., Lalonde P., Nicole L., Lesage A., Stip E. CANTAB explicit memory is less impaired in addicted schizophrenia patients. Brain Cogn. 2005, 59(1):38-42.
94. Prochaska J.O., DiClemente C.C. Stages and processes of self-change of smoking: toward an integrative model of change. J. Consult Clin. Psychol. 1983, 51(3):390-395.
95. Prochaska J.O., Velicer W.F., Rossi J.S., Goldstein M.G., Marcus B.H., Rakowski W., Fiore C., Harlow L.L., Redding C.A., Rosenbloom D., Rossi S.R. Stages of change and decisional balance for 12 problem behaviors. Health Psychol. 1994, 13(1):39-46.
96. Regier D.A., Farmer M.E., Rae D.S., Locke B.Z., Keith S.J., Judd L.L., Goodwin F.K. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990, 264:2511-2518.
97. Ries R.K., Ellingson T. A pilot assessment at one month of 17 dual diagnosis patients. Hosp. Community Psychiatry 1990, 41(11):1230-1233.
98. Rollnick S., Heather N., Gold R., Hall W. Development of a short 'readiness to change' questionnaire for use in brief, opportunistic interventions among excessive drinkers. Br. J. Addict. 1992, 87(5):743-754.
99. Schaub M., Fanghaenel K., Stohler R. Reasons for cannabis use: patients with schizophrenia versus matched healthy controls. Aust. N. Z. J. Psychiatry 2008, 42:1060-1065.
100. Schneier F.R., Siris S.G. A review of psychoactive substance use and abuse in schizophrenia patterns of drug choice. J. Nerv. Ment. Dis. 1987, 175(11):641-652.
101. Schofield D., Tennant C., Nash L., Degenhardt L., Cornish A., Hobbs C., Brennan G. Reasons for cannabis use in psychosis. Aust. N. Z. J. Psychiatry 2006, 40:570-574.
102. Sevy S., Robinson D.G., Solloway S., Alvir J.M., Woerner M.G., Bilder R., Goldman R., Lieberman J., Kane J. Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. Acta Psychiatr. Scand. 2001, 104:367-374.
103. Sorbara F., Liraud F., Assens F., Abalan F., Verdoux H. Substance use and the course of early psychosis: a 2-year follow-up of first-admitted subjects. Eur. Psychiatry 2003, 18:133-136.
104. Spencer C., Castle D., Michie P.T. Motivations that maintain substance use among individuals with psychotic disorders. Schizophr. Bull. 2002, 28(2):233-247.
105. Test M.A., Wallisch L.S., Allness D.J., Ripp K. Substance use in young adults with schizophrenic disorders. Schizophr. Bull. 1989, 15(3):465-476.
106. Tien A.Y., Anthony J.C. Epidemiological analysis of alcohol and drug use as risk factors for psychotic experiences. J. Nerv. Ment. Dis. 1990, 178:473-480.
107. Todd J., Green G., Harrison M., Ikuesan B.A., Self C., Pevalin D.J., Baldacchino A. Social exclusion in clients with comorbid mental health and substance misuse problems. Soc. Psychiatry Psychiatr. Epidemiol. 2004, 39(7):581-587.
108. Tracy J.I., Josiassen R.C., Bellack A.S. Neuropsychology of dual diagnosis: understanding the combined effects of schizophrenia and substance use disorders. Clin. Psychol. Rev. 1995, 15:67-97.
109. United Nations Office on Drugs and Crime, 2010. World Drug Report. UNODC. (http://www.unodc.org/documents/wdr/WDR_2010/World_Drug_Report_2010_lo-res.pdf).
110. van Os J., Bak M., Hanssen M., Bijl R.V., de Graaf R., Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am. J. Epidemiol. 2002, 156:319-327.
111. van Os J., Rutten B.P., Poulton R. Gene-environment interactions in schizophrenia: review of epidemiological findings and future directions. Schizophr. Bull. 2008, 34(6):1066-1082.
112. Velasquez M.M., Carbonari J.P., DiClemente C.C. Psychiatric severity and behavior change in alcoholism: the relation of the transtheoretical model variables to psychiatric distress in dually diagnosed patients. Addict. Behav. 1999, 24(4):481-496.
113. Weiser M., Knobler H.Y., Noy S., Kaplan Z. Clinical characteristics of adolescents later hospitalized for schizophrenia. Am. J. Med. Genet. 2002, 114:949-955.
114. Wells, E.A., Calsyn, D.A., Clark, L.L., Jackson, T.R., 1998. Motivational enhancement to increase treatment readiness among stimulant users: A pilot evaluation. In: Harris, L.S. (Ed.), Problems on Drug Dependence 1997: Proceeding of the 59th annual scientific meeting of The College on Problems of Drug Dependence, Inc. National Institute of Drug Abuse Research Monograph 178 (NIH Publication No. 98-4305). National Institute on Drug Abuse, Rockville, MD, 97.
115. Wiles N.J., Zammit S., Bebbington P., Singleton N., Meltzer H., Lewis G. Self-reported psychotic symptoms in the general population: results from the longitudinal study of the British National Psychiatric Morbidity Survey. Br. J. Psychiatry 2006, 188:519-526.
116. Zammit S., Allebeck P., Andreasson S., Lundberg I., Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. Br. Med. J. 2002, 325:1195-1199.
117. Zammit S., Moore T.H., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., Lewis G. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br. J. Psychiatry 2008, 193(5):357-363.
118. Zhang A.Y., Harmon J.A., Werkner J., McCormick R.A. The long-term relationships between the motivation for change and alcohol use severity among patients with severe and persistent mental illness. J. Addict. Dis. 2006, 25:121-128.
119. Zhang A.Y., Harmon J.A., Werkner J., McCormick R.A. Impacts of motivation for change on the severity of alcohol use by patients with severe and persistent mental illness. J. Stud. Alcohol. 2004, 65(3):392-397.
120. Ziedonis D.M., Trudeau K. Motivation to quit using substances among individuals with schizophrenia: implications for a motivation-based treatment model. Schizophr. Bull. 1997, 23(2):229-238.
121. Zuardi A.W., Crippa J.A.S., Hallak J.E.C., Moreira F.A., Guimaráes F.S. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz. J. Med. Biol. Res. 2006, 39:421-429.